


Chiral separation of novel iminonaringenin derivatives

Meriem Bouanini¹ | Nasser Belboukhari¹ | J. Carlos Menéndez² | Khaled Sekkoum¹ | Abdelkarim Cheriti³ | Hassan Y. Aboul-Enein⁴ 

¹Bioactive Molecules and Chiral Separation Laboratory, Faculty of Science and Technology, University of Bechar, Bechar, Algeria

²Pharmaceutical and Organic Chemistry Department, School of Pharmacy, University of Madrid (Complutense), Madrid, Spain

³Phytochemistry and Organic Synthesis Laboratory, Faculty of Science and Technology, University of Bechar, Bechar, Algeria

⁴Pharmaceutical and Medicinal Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Center, Cairo, Egypt

Correspondence

Hassan Y. Aboul-Enein, Pharmaceutical and Medicinal Chemistry Department, Pharmaceutical and Drug Industries Research Division, National Research Center, Dokki, Cairo, Egypt.
Email: haboulenein@yahoo.com

Abstract

A series of 4-iminonaringenin derivatives **2-6** have been prepared in good overall yields from a condensation reaction between naringenin and primary amines. The structures of all products were confirmed by ultraviolet, infrared, proton nuclear magnetic resonance, and carbon-13 nuclear magnetic resonance spectroscopic techniques. These derivatives were analyzed by high-performance liquid chromatography using polysaccharide-based chiral stationary phases, namely, Chiralpak IB and Chiralcel OD, using various mobile phases. 2-Propanol showed a high enantioselectivity for naringenin and its derivatives using achiral column containing immobilized polysaccharides (Chiralpak IB).

KEYWORDS

Chiralcel OD, Chiralpak IB, HPLC, *N*-4-iminonaringenins, naringenin, naringenin, polysaccharide-based chiral stationary phases

1 | INTRODUCTION

Flavonoids are polyphenolic compounds that are widely distributed in plants and preserve their health against infections and parasites.^{1,2} They possess beneficial effects against several serious human diseases, such as AIDS, cancer, cardiovascular disease, and neurodegenerative disorders.³⁻⁵ In vitro experimental studies show that flavonoids act as antioxidants, antimicrobials, antivirals, and anti-inflammatories.⁶⁻⁹ Naringenin, (S)-7-(((2*S*,3*R*,4*R*,5*S*,6*R*)-4,5-dihydroxy-6-(hydroxymethyl)-3-(((2*S*,3*R*,4*R*,5*R*,6*S*)-3,4,5-trihydroxy-6-ethyl tetrahydro-2*H*-pyran-2-yl)oxy) tetrahydro-2*H*-pyran-2-yl)oxy)-5-hydroxy-2-(4-hydroxyphenyl) chroman-4-one, Figure 1, is the conjugate of naringenin with neohesperidose (rhamnosyl- α -1,2- glucose).¹⁰ It is found in abundance in citrus, especially grape fruit, being partly responsible for its bitter taste. Naringenin shows

various bioactivities potentially useful in promoting human health, being an antioxidant that acts as a reactive oxygen species scavenger, with neuroprotective properties.¹¹ It has anticancer effects^{12,13} and has been investigated as a cancer preventive agent. Some naringenin derivatives have also been investigated for their pharmacological properties; for instance, its oxime was screened for antioxidant activity by Ozyurek et al,^{14,15} and several naringenin derivatives have been also studied in this regard.^{16,17} It is relevant to note that naringenin inhibits some drug-metabolizing cytochrome P450 enzymes, including CYP3A4 and CYP1A2, which may result in drug-drug interactions.¹⁸ The ingestion of naringenin and related flavonoids can also affect the intestinal absorption of certain drugs, leading to either an increase or decrease in circulating drug levels. To avoid interference with drug absorption and metabolism, the




FIGURE 1 Structure of naringin

consumption of citrus (especially grapefruit) and other juices with medications is advised against. All these pharmacological properties are due to naringenin, which is generated by the liver enzyme naringinase by successively hydrolyzing its 2 glycoside bonds. This enzyme occurs widely in nature and is of potential industrial interest for citrus juice debittering and other applications.¹⁹

Because of the presence of a stereogenic center at their C2 position, flavanones can exist in enantiomeric forms. For many years, the research in our laboratory has been directed towards the synthesis and chiral separation of flavanone derivatives.^{20–22} In the case of naringin, owing to the presence of additional stereo centers at the neohesperidoside moiety, the 2 possible species are diastereomers (epimers), but naringenin exists as 2 enantiomers. It is worth mentioning at this point that epimerization processes at the naringin and naringenin C-2 stereo center are well known,²³ and in fact, the commercially available materials consist of mixtures of both possible isomers at this stereo center. Interestingly, both enantiomers of naringenin have shown divergent biological properties,^{24,25} which make their separation particularly important.

The aim of this work is to study the chiral separation of iminonaringenin diastereoisomer by high-performance liquid chromatography (HPLC) and to optimize the analytical conditions using polysaccharide-based chiral stationary phases (CSPs). These derivatives were synthesized in 1 step by reaction between naringenin and primary amines.

2 | MATERIALS AND METHODS

2.1 | Reagents and solvents

Naringenin was purchased from Sigma-Aldrich (Schnelldorf, Germany).

The primary amines used were propylamine, isobutylamine, *tert*-butylamine, 2-furfurylamine, and hexylamine, all of which were purchased from FlukaBuches.

2.2 | Synthesis of iminonaringenins 2–6

Naringenin (1 mmol) and the suitable primary amine (2 mmol) were refluxed in methanol (5 mL) for 24 hours. The mixture was cooled to room temperature, and, by adding 10 mL diethyl ether, a solid precipitated out, which was filtered and recrystallized from ethanol.

2.3 | Characterization data for compounds 2–6

2-(4-Hydroxy phenyl)-4-(propylimino) chromane-5,7-diol (2): yellow powder, yield 65%, mp 200°C to 202°C, UV_{max} (MeOH): 239 (band I); 315 (band II), IR (KBr, cm^{-1}): 3377 (OH, strong), 2967 (CH_3), 2962–2918 (CH_2), 1601 (CN), 1514 ($C=C$), 1066 ($C-O$), 1H NMR (250 MHz, MeOD, δ ppm) 7.31 (2H, d, $J = 7.5$ Hz, H-2', and H-6'), 6.29 (2H, d, $J = 7.5$ Hz, H-3', and H-5'), 6.04 (1H, s, H-8), 5.0 (1H, dd, $J = 7.5$ and 2.5 Hz, H-2), 3.60 (2H, m, $N-CH_2$), 2.86 (1H, dd, $J = 12.5$ and 2.5 Hz, H_3^b), 2.62 (1H, dd, $J = 12.5$ and 7.5 Hz, H_3^a), 1.27 (2H, m, CH_2), 0, 71 (3H, m, CH_3). ^{13}C NMR (63 MHz, MeOD, ppm): 168.1 (C-4), 164.4 (C-7), 159.9 (C-5), 157.4 (C-4'), 156.7 (C-9), 128.7 (C-2', C6'), 116.9 (C-3', C5'), 95.1 (C-6), 94.2 (C-8), 76.7 (C-2), 59.8 (CH_2-N), 40.3 (C-3), 21.1 (CH_2-CH_2-N), 11.3 (CH_3).

2-(4-Hydroxy phenyl)-4-(isobutylimino) chromane-5,7-diol (3): brown yellowish powder, yield 60%, mp 210°C to 212°C, UV_{max} (MeOH): 225 (band I); 310 (band II), IR (KBr, cm^{-1}): 3388 (OH, strong), 1607 ($C=N$), 1508 ($C=C$), 1126 ($C-O$).

1H NMR (250 MHz, MeOD, δ ppm) 7.22 (2H, d, $J = 7.5$ Hz, H-2', and H-6'), 6.72 (2H, d, $J = 7.5$ Hz, H-3', and H-5'), 6.50 (2H, m, H-6, and H-8), 5.07 (1H, dd, $J = 7.5$ and 2.5 Hz, H-2), 3.06 (1H, d, $N-CH$), 2.85 (1H, dd, $J = 2.5$ and 12.5 Hz, H_3^b), 2.61 (1H, dd, $J = 7.5$ and 12.5 Hz, H_3^a), 1.32 (6H, m, 2 CH_3).

^{13}C NMR (63 MHz, MeOD, ppm): 168.1 (C-4, C-7), 163.6 (C-5), 160.0 (C-9), 158.2 (C-4'), 129, 5 (C-1'), 128.7 (C-2', C6'), 115.6 (C-3', C5'), 95.0 (C-6), 94.6 (C-8), 77.7 (C-2), 44.6 ($CH-N$), 39.6 (C3), 24.3 (2 CH_3).

2-(4-Hydroxyphenyl)-4-(*tert*-butylimino) chromane-5,7-diol (4): brown powder, yield 62%, mp 206°C to 208°C, UV_{max} (MeOH): 230 (band I); 300 (band II), IR (KBr, cm^{-1}): 3420 (OH, strong), 1569 ($C=N$), 1514 ($C=C$), 1181 ($C-O$). 1H NMR (250 MHz, MeOH, δ ppm) 7.54 (2H, d, $J = 7.2$ Hz, H-2', and H-6'), 6.34 (2H, d, $J = 7.2$ Hz, H-3', and H-5'), 5.79 (2H, m, H-6, and H-8), 5.12 (1H, dd, $J = 7.5$ and 2.5 Hz, H-2), 2.95 (1H, dd, $J = 12.5$ and 2.5 Hz, H_3^b), 2.64 (1H, dd, $J = 12.5$ and 7.5, H_3^a), 1.30 (9H, s, 3 CH_3).

^{13}C NMR (63 MHz, MeOD, ppm): 164.2 (C-4), 164.1 (C-7), 162.7 (C-5), 160.0 (C-9), 157.4 (C-4'), 130.9 (C-1'),

127.9 (C-2',-C6'), 126.8 (C-3',C5'), 95.0 (C-6), 94.6 (C-8), 78.3 (C-2), 49, 9 (C-N), 40.7 (C3), 30.4 (3CH₃).

2-(4-Hydroxy phenyl)-4-(furfurylimino)chromane-5,7-diol (5): brown powder, yield 70%, mp 196°C to 198°C, UV_{max} (MeOH): 225 (band I); 320 (band II), IR (KBr, cm⁻¹): 3366 (OH, strong), 1607 (C=N), 1514 (C=C), 1170 (C—O).

¹H NMR (250 MHz, MeOD, δppm), 7.51 (1H, d, *J* = 7.5 Hz, H-3''), 7.31 (2H, d, *J* = 7.5 Hz, H-2' and H-6'), 6.82 (2H, d, *J* = 4.61 Hz, H-3', and H-5'), 6.48 (1H, m, H-4''), 6.28 (3H, m, H-6, 8, and 5''), 5.79 (1H, dd, *J* = 7.5 and 2.5 Hz, H-2), 4.81 (2H, s, N—CH₂), 2.90 (1H, dd, *J* = 15 and 2.5 Hz, H3^b), 2.73 (1H, dd, *J* = 15 and 7.5 Hz, H3^a).

¹³C NMR (63 MHz, MeOD, ppm): 168.5 (C-4), 167.5 (C-7), 162.5 (C-5), 159.9 (C-9), 158.1 (C-4'), 152.1 (C-1''), 143.1 (C-3''), 129.7 (C-1'), 128.8 (C-2' and 6'), 115.6 (C-3' and 5'), 110.6 (C-4''), 108.2 (C-10), 107.7 (C-5''), 95.3 (C-6), 94.8 (C-8), 77.7 (C-2), 44.2 (CH₂—N), 39.1 (C-3).

2-(4-Hydroxy phenyl)-4-(hexylimino) chromane-5,7-diol (6): yellow powder, yield 45%, mp 194°C to 196°C, UV_{max} (MeOH): 225 (band I); 315 (band II), IR (KBr, cm⁻¹): 3382 (OH, strong), 1596 (C=N), 1552 (C=C), 1125 (C—O).




FIGURE 2 Synthesis of 4-iminonaringenins 2-6





FIGURE 3 Structures and yields of 4-iminonaringenin derivatives 2-6

¹H NMR (250 MHz, MeOD, δppm) 7.22 (2H, d, *J* = 7.5 Hz, H-2', and H-6'), 6.71 (2H, d, *J* = 7.5 Hz, H-3', and H-5'), 6.10 (1H, t, H-6), 5.76 (1H, dd, *J* = 7.5 and 2.5 Hz, H-2), 3.40 (2H, m, H1''), 3.20 (1H, dd, *J* = 15 and 2.5 Hz, H3^b) 2.68 (1H, dd, *J* = 7.5 and 15 Hz, H3^a), 1.63 (2H, m, H2''), 1.37 (2H, m, H5''), 1.29 (6H, m, H3'', 4''), 0.82 (3H, m, H6'').

¹³C NMR (63 MHz, MeOD, ppm): 167.9 (C-4 and C-7), 163.5 (C-5), 160.0 (C-9), 158.2 (C-4'), 129.7 (C-1'), 128.8 (C-2'&6'), 115.6 (C-3' and 5'), 95.6 (C-6), 94.7 (C-8), 77.7 (C-2), 45.1 (C-1''), 39.7 (C-3), 31.3 (C-2'' and C-4''), 26.5 (C-3''), 22.5 (C-5''), 14.3 (C-6'').

2.4 | Chromatographic separation

The enantiomeric separations were conducted on a SHIMADZU LC 20-A system equipped with a vacuum degasser, PerkinElmer (Norwalk, Connecticut), Shimadzu LC 20 AD (Kyoto, Japan) 200 LC pump, injector with 20 μL Rheodyne 1907 sample loop equipped with a UV detector Shimadzu SPD-20 A (Kyoto, Japan). All analytes were dissolved in methanol at concentrations in a 0.5 to 1 mg mL⁻¹ range. Injection volume was 20 μL, and the UV detector was set at 280 nm. Chromatographic separa-



tions were conducted at ambient temperature under isocratic mode at a flow rate of 0.2 to 0.4 mL min⁻¹, which may be changed in particular cases.

2.5 | Chiral stationary phases

Two polysaccharide CSPs were evaluated in this study, namely, cellulose derivatives: Chiralcel OD and Chiralpak IB purchased from Chiral Technologies Europe (Illkirch, France). HPLC-grade solvents used were 2-propanol, methanol, and ethanol.

3 | RESULTS AND DISCUSSION

3.1 | Synthesis of 4-iminonaringenin derivatives

The synthesis of 4-iminonaringenin derivatives (compounds **2-6**) was achieved directly from naringenin **1**, which was treated with various primary amines in refluxing methanol without the addition of any external catalyst as shown in Figure 2. The reaction yields ranged 45% to 70% as shown in Figure 3. The structures of the synthesized compounds were confirmed by the analysis




FIGURE 5 Chromatograms of enantiomeric separation of compounds **1** and **5** under polar organic phase mode using 100% EtOH in Chiralpak IB, temperature 25°C, and UV detector set at 280 nm.




FIGURE 6 Chromatograms showing the enantiomeric separation of compounds **1**, **2**, **3**, **4**, **5**, and **6** under polar organic phase mode using 100% 2-propanol in Chiralpak IB, temperature 25°C, and UV detector set at 280 nm

TABLE 1 Chromatographic data for the separation of 4-iminonaringenins derivatives by Chiral HPLC

CSP	Eluent, % of alcohol	Product	Flow Rate, mL/min	t_1	t_2	k_1	k_2	Rs	α
Chiralpak IB	2-Propanol	1	0.2	24.70	29.32	5.17	6.32	2.77	1.22
		2		24.24	28.81	5.06	6.02	3.00	1.19
		3		23.62	27.46	4.90	5.86	2.30	1.20
		4		24.47	28.83	5.11	6.62	2.84	1.29
		5		26.42	32.09	5.60	7.02	2.83	1.25
		6		26.33	31.89	5.58	6.97	2.78	1.24
	EtOH	1	0.4	9.59	10.99	1.39	1.74	2	1.25
		2		—	—	—	—	—	—
		3		—	—	—	—	—	—
		4		—	—	—	—	—	—
		5		9.77	11.34	1.44	1.83	1.57	1.27
		6		—	—	—	—	—	—
	MeOH	1	0.4	8.59	9.01	1.14	1.25	0.84	1.09
		2		—	—	—	—	—	—
		3		—	—	—	—	—	—
		4		8.59	9.03	1.14	1.25	0.88	1.09
		5		—	—	—	—	—	—
		6		—	—	—	—	—	—
Chiralcelk OD	2-Propanol	1	0.2	22.62	37.89	4.65	8.47	2.34	1.82
		2		—	—	—	—	—	—
		3		—	—	—	—	—	—
		4		—	—	—	—	—	—
		5		24.09	—	5.02	—	—	—
		6		—	—	—	—	—	—
	EtOH	1	0.4	12.96	13.94	2.24	2.48	0.65	1.10
		2		7.50	—	0.87	—	—	—
		3		13.23	13.96	2.30	2.49	0.36	1.08
		4		12.63	13.88	2.15	2.47	0.62	1.14
		5		7.15	7.46	0.78	0.86	0.62	1.10
		6		—	—	—	—	—	—
	MeOH	1	0.4	7.39	13.91	0.84	2.47	0.68	1.88
		2		—	—	—	—	—	—
		3		—	—	—	—	—	—
		4		—	—	—	—	—	—
		5		—	—	—	—	—	—
		6		—	—	—	—	—	—

Abbreviations: HPLC, high-performance liquid chromatography; CSP, chiral stationary phase.

of their spectral data, including UV/IR (the spectra of all products did not show any absorption due to the presence of C=O).

3.2 | Enantioseparation of the 4-iminonaringenin derivatives

The chromatographic conditions were optimized to achieve the best separation of the 4-iminonaringenin enantiomers under polar organic phase and normal phase modes using cellulose tris (3,5-dimethylphenylcarbamate) coated on 10 μ m silica-gel (Chiralcel OD) and cellulose tris (3,5-dimethyl phenylcarbamate) immobilized on 5 μ m silica-gel (Chiralpak IB), whose structure is shown in Figure 4. HPLC enantioseparation of naringenin has been previously reported on polysaccharide CSPs,²⁶ but

its imino derivatives are unexplored in this regard. Polysaccharide-based (cellulose and amylose) CSPs have proved to be very efficient materials in HPLC (in both normal and reversed and polar organic phase modes) for the resolution of chiral drugs. The chiral discrimination power of these polysaccharide phases stems from complex interactive forces (which have not been fully elucidated yet) with the solutes. In summary, a combination of hydrophobic interactions, hydrogen bonding, dipole-dipole interactions, and charge transfer (π - π) formation is believed to explain the chiral recognition mechanisms.²⁷⁻³⁰ The difference in the chiral recognition ability between the amylose and the cellulose may be due the difference in the polysaccharide configuration. Amylose possesses a more helical configuration than cellulose that is more rigid and linear in nature.

The chiral separation of the 4-iminonaringenin derivatives was assayed in normal and organic polar phase modes. However, in normal phase mode, no separation was obtained using mobile phases consisting of hexane-EtOH: 95-5, 50:50 v/v for the compounds under study. However, under organic polar phase mode using 100% alcohol, efficient enantioseparations were achieved. In the first experiment, naringenin was resolved on Chiralpak IB and Chiralcel OD using a mobile phase consisting of neat MeOH albeit with a low resolution ($R = 0.8$ under Chiralpak IB and $R = 0.68$ under Chiralcel OD).

Our next studies showed that compound **5** and naringenin could be separated in a mobile phase consisting of 100% EtOH under Chiralpak IB with good selectivity factors, $\alpha = 1.27$ and 1.25 , respectively (Figure 5). However, no separation was achieved on Chiralpak IB and for compounds **2**, **4**, and **6** when using a 100% MeOH or 100% EtOH as mobile phases.

The use of 2-propanol led to the best selectivity values for the resolution for all 4-iminonaringenin enantiomers. Baseline separation $R_s > 1.5$ was always achieved on cellulose-based CSPs for the reference naringenin **1** and all products **2-6** (Figure 6). The resolution value ranged from 2.3 to 3.0. The best separation was observed on the Chiralpak IB column using 2-propanol for compound **2**, for which $R_s = 3$. All experiments were performed at 25°C.

The selection of organic solvent as the mobile phase in polar organic phase mode is important to achieve successful enantioseparation as well and the type of CSPs selected. The effect of mobile phase-composition temperature and flow rate on resolution R_s and selectivity α was examined. The optimal conditions were found to involve the use of a mobile phase of 100% 2-propanol at a flow rate of 0.2 mL/min on a Chiralpak IB column maintained at ambient temperature (Figure 6). The associated chromatographic parameters are collected in Table 1.

4 | CONCLUSION

This study describes the synthesis of various 4-iminonaringenin derivatives and discusses their enantioseparation using 2 polysaccharide-based CSPs, namely, Chiralpak IB and Chiralcel OD. The best resolution for naringenin and 4-iminonaringenins was achieved when using immobilized type Chiralpak IB columns under polar organic phase mode using 100% 2-propanol as the mobile phase.

ORCID

Hassan Y. Aboul-Enein  <http://orcid.org/0000-0003-0249-7009>

REFERENCES

1. Wang X, Cheng S. Solvent-free synthesis of flavanones over aminopropyl-functionalized, SBA15. *Catal Commun.* 2006;7:689-695.
2. Maltese F, Erkelens C. Identification of natural epimeric flavanone glycosides by NMR spectroscopy. *Food Chem.* 2009;116:575-579.
3. Havsteen B. Flavonoids, a class of natural products of high pharmacological potency. *Biochem Pharmacol.* 1983;32:1141-1148.
4. Mantas A, Deretey E, Ferretti FH, Estrada MR, Csizmadia IG. Structural analysis of flavonoids with anti-HIV activity. *THEOCHEM.* 2000;504:171-179.
5. Batra P, Sharma AK. Anti-cancer potential of flavonoids: recent trends and future perspectives. *Biotech.* 2013;3:439-459.
6. van Acker SA, van Balen GP, van den Berg DJ, Bast A, van der Vijgh WF. Influence of iron chelation on the antioxidant activity of flavonoids. *Biochem Pharmacol.* 1998;56:935-943.
7. Williams RJ, Spencer JP, Rice-Evans C. Flavonoids: antioxidants or signaling molecules. *Free Radic Biol Med.* 2004;36:838-849.
8. Ferguson PJ, Kurowska EM, Freeman DJ. In vivo inhibition of growth of human tumor lines by flavonoid fractions from cranberry extract. *Nutr Cancer.* 2006;56:86-94.
9. So FV, Guthrie N, Chambers AF, Moussa M, Carroll KK. Inhibition of human breast cancer cell proliferation and delay of mammary tumorigenesis by flavonoids and citrus juices. *Nutr Cancer.* 1996;26:167-181.
10. Akiyama T, Yamada T, Maitani T. Naringin glycosides α glycosylated on ring B found in the natural food additive. *Biotechnol Biochem.* 2000;64:2246-2249.
11. Kim HK, Song JY, Park HJ, Park HK, Yun DH, Chung JH. Naringin protects against rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells. *Korean J Physiol Pharmacol.* 2009;13:281-285.
12. Lia H, Yanga B, Huang J, et al. Naringenin inhibits growth potential of human triple-negative breast cancer cells by targeting β -catenin signaling pathway. *Toxicol Lett.* 2013;220:219-228.
13. Cirm S, Ferlazzo N, Lombardo GE, et al. Chemopreventive agents and inhibitors of cancer hallmarks: may citrus offer new perspectives? *Nutrients.* 2016;8:698.
14. Ozyurek M, Akpınar D, Bener M, Turkkan B, Guclu K, Apak R. Novel oxime based flavanone, naringin-oxime: synthesis, characterization and screening for antioxidant activity. *Chem Biol Interact.* 2014;212:40-46.
15. Jodeh S, Shawarab N, Jaradat N, Warad I, Hussein F, El-Masri M. Synthesis and biological activities of a novel naringin based heterocyclic derivatives. *Mor J Chem.* 2016;3:242-250.

16. Duganath N, Sridhar C, Jaya veera KN. Synthesis, characterization and antioxidant activity of some novel naringin semi synthetic derivatives. *Indo Am J Pharm Res.* 2013;3:1547-1559.
17. Fuhr U, Kummert AL. The fate of naringin in humans: a key to grapefruit juice-drug interactions. *Clin Pharmacol Ther.* 1995;58:365-373.
18. Ribeiro MH. Naringinases: occurrence, characteristics and applications. *Appl Microbiol Biotechnol.* 2011;90:1883-1895.
19. Belboukhari N. Enantioseparation of hydroxyl flavanones on amylose and cellulose CSPS by HPLC methods. *J Chromatogr Sep Tech.* 2012;3:67-68.
20. Lahmer N, Belboukhari N, Cheriti A. Méthodes et techniques de la séparation chirale des flavanones. *Phytochem Biosub* 2011. 2011;5:1-4.
21. Rahou I, Sekkoum K, Belboukhari N, Cheriti A, Aboul-Enein HY. Liquid chromatographic separation of novel 4-amino-flavanes series diastereomers on a polysaccharide-type chiral stationary phase. *J Chromatogr Sci.* 2016;54:1787-1793.
22. Caccamese S, Chilleemi R. Racemization at C-2 of naringin in pummelo (*Citrus grandis*) with in creasing maturity determined by chiral high-performance liquid chromatography. *J Chromatogr A.* 2009;1217:1089-1093.
23. Lu WJ, Ferlito V, Xu C, Flockhart DA, Caccamese S. Enantiomers of naringenin as pleiotropic, stereoselectiveinhibitors of cytochrome P450 isoforms. *J Chir.* 2011;23:891-896.
24. Curti V, Di Lorenzo A, Rossi D, et al. Enantioselective modulatory effects of naringenin enantiomers on the expressionl evels of *miR-17-3p* involved in endogenous antioxidant defenses. *Nutrients.* 2017;9:1-13.
25. Aboul-Enein HY. High-performance liquid chromatographic enantioseparation of drugs containing multiple chiral centers on polysaccharide-type chiral stationary phases. *J Chromatogr A.* 2001;906:185-193.
26. Mesplet N, Saito Y, Morin P, Agrofoglio LA. Liquid chromatographic separation of phosphoramidate diastereomers on a polysaccharide-type chiral stationary phase. *J Chromatogr.* 2003;983:115-124.
27. Belboukhari N, Cheriti A, Roussel C, Vanthuyne N. Chiral separation of hesperidin and naringin and its analysis in a butanol extract of *Launeae arborescens*. *Nat Prod Res.* 2010;247:669-681.
28. Rahou I, Belboukhari N, Sekkoum K, Cheriti A, Aboul-Enein HY. Chiral separation of 4-iminoflavan derivatives on several polysaccharide-based chiral stationary phases by HPLC. *Chromatographia.* 2014;77:1195-1201.
29. Cirilli R, Ferretti R, De Santis E, Gallinella B, Zanitti L, La Torre F. High-performance liquid chromatography separation of enantiomers of flavanone and 2'-hydroxychalcone under reversed-phase conditions. *J Chromatogr A.* 2008;1190 nnnnnn:95-101.
30. Roussel C, Bonnet B, Piederriere A, Suteu C. Enantioselective correlation between retention factor and lipophilicity index in chiral separation on cellulose and amylose tris(3,5-dimethylphenylcarbamate) CSPs in reversed mode: a case study. *J Chir.* 2001;13:56-61.

How to cite this article: Bouanini M, Belboukhari N, Menéndez JC, Sekkoum K, Cheriti A, Aboul-Enein HY. Chiral separation of novel iminonaringenin derivatives. *Chirality.* 2018;30: 484–490. <https://doi.org/10.1002/chir.22812>